In Brief: Genzyme/Abiomed
This article was originally published in The Gray Sheet
Executive Summary
Genzyme/Abiomed: Abiomed's board authorizes the sale to Genzyme of approximately 1.15 mil. shares of its common stock for $13 per share. With the investment, Genzyme will own approximately 14% of Abiomed, a developer of artificial heart devices. The two companies also are "discussing collaborative agreements that would allow them to jointly develop and commercialize" advanced products for "cardiovascular and other surgical markets." Genzyme and Abiomed will focus on products for minimally invasive cardiac surgery, among other areas, Abiomed says...
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.